Literature DB >> 17383022

The impact of morphine after a spinal cord injury.

Michelle A Hook1, Grace T Liu, Stephanie N Washburn, Adam R Ferguson, Anne C Bopp, John R Huie, James W Grau.   

Abstract

Nociceptive stimulation, at an intensity that elicits pain-related behavior, attenuates recovery of locomotor and bladder functions, and increases tissue loss after a contusion injury. These data imply that nociceptive input (e.g., from tissue damage) can enhance the loss of function after injury, and that potential clinical treatments, such as pretreatment with an analgesic, may protect the damaged system from further secondary injury. The current study examined this hypothesis and showed that a potential treatment (morphine) did not have a protective effect. In fact, morphine appeared to exacerbate the effects of nociceptive stimulation. Experiment 1 showed that after spinal cord injury 20mg/kg of systemic morphine was necessary to induce strong antinociception and block behavioral reactivity to shock treatment, a dose that was much higher than that needed for sham controls. In Experiment 2, contused rats were given one of three doses of morphine (Vehicle, 10, 20mg/kg) prior to exposure to uncontrollable electrical stimulation or restraint alone. Despite decreasing nociceptive reactivity, morphine did not attenuate the long-term consequences of shock. Rats treated with morphine and shock had higher mortality rates, and displayed allodynic responses to innocuous sensory stimuli three weeks later. Independent of shock, morphine per se undermined recovery of sensory function. Rats treated with morphine alone also had significantly larger lesions than those treated with saline. These results suggest that nociceptive stimulation affects recovery despite a blockade of pain-elicited behavior. The results are clinically important because they suggest that opiate treatment may adversely affect the recovery of function after injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383022      PMCID: PMC1965266          DOI: 10.1016/j.bbr.2007.02.035

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  61 in total

Review 1.  Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain.

Authors:  J Mao; D J Mayer
Journal:  Ann N Y Acad Sci       Date:  2001-03       Impact factor: 5.691

Review 2.  Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.

Authors:  Robert H Dworkin; Miroslav Backonja; Michael C Rowbotham; Robert R Allen; Charles R Argoff; Gary J Bennett; M Catherine Bushnell; John T Farrar; Bradley S Galer; Jennifer A Haythornthwaite; David J Hewitt; John D Loeser; Mitchell B Max; Mario Saltarelli; Kenneth E Schmader; Christoph Stein; David Thompson; Dennis C Turk; Mark S Wallace; Linda R Watkins; Sharon M Weinstein
Journal:  Arch Neurol       Date:  2003-11

Review 3.  Central sensitization and LTP: do pain and memory share similar mechanisms?

Authors:  Ru-Rong Ji; Tatsuro Kohno; Kimberly A Moore; Clifford J Woolf
Journal:  Trends Neurosci       Date:  2003-12       Impact factor: 13.837

4.  Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats.

Authors:  Vasudeva Raghavendra; Flobert Y Tanga; Joyce A DeLeo
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

Review 5.  Nociception, pain, and antinociception: current concepts.

Authors:  W Riedel; G Neeck
Journal:  Z Rheumatol       Date:  2001-12       Impact factor: 1.372

6.  Types and effectiveness of treatments used by people with chronic pain associated with spinal cord injuries: influence of pain and psychosocial characteristics.

Authors:  E G Widerström-Noga; D C Turk
Journal:  Spinal Cord       Date:  2003-11       Impact factor: 2.772

7.  Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain.

Authors:  Imre Szabo; Xiao-Hong Chen; Li Xin; Martin W Adler; O M Z Howard; Joost J Oppenheim; Thomas J Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-18       Impact factor: 11.205

8.  Instrumental learning within the spinal cord: IV. Induction and retention of the behavioral deficit observed after noncontingent shock.

Authors:  Eric D Crown; Adam R Ferguson; Robin L Joynes; James W Grau
Journal:  Behav Neurosci       Date:  2002-12       Impact factor: 1.912

9.  Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study.

Authors:  Manabu Kakinohana; Martin Marsala; Christopher Carter; J Kenneth Davison; Tony L Yaksh
Journal:  Anesthesiology       Date:  2003-04       Impact factor: 7.892

10.  Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-01       Impact factor: 6.167

View more
  40 in total

1.  Validity of acute and chronic tactile sensory testing after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Leslie M Clark; Karen J Hutchinson; Anne D Kloos; Lesley C Fisher; D Michele Basso
Journal:  Exp Neurol       Date:  2010-07-17       Impact factor: 5.330

Review 2.  Learning to promote recovery after spinal cord injury.

Authors:  James W Grau; Rachel E Baine; Paris A Bean; Jacob A Davis; Gizelle N Fauss; Melissa K Henwood; Kelsey E Hudson; David T Johnston; Megan M Tarbet; Misty M Strain
Journal:  Exp Neurol       Date:  2020-04-28       Impact factor: 5.330

Review 3.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

4.  An IL-1 receptor antagonist blocks a morphine-induced attenuation of locomotor recovery after spinal cord injury.

Authors:  Michelle A Hook; Stephanie N Washburn; Georgina Moreno; Sarah A Woller; Denise Puga; Kuan H Lee; James W Grau
Journal:  Brain Behav Immun       Date:  2010-10-23       Impact factor: 7.217

5.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

6.  Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation.

Authors:  Peter M Grace; Keith A Strand; Erika L Galer; Daniel J Urban; Xiaohui Wang; Michael V Baratta; Timothy J Fabisiak; Nathan D Anderson; Kejun Cheng; Lisa I Greene; Debra Berkelhammer; Yingning Zhang; Amanda L Ellis; Hang Hubert Yin; Serge Campeau; Kenner C Rice; Bryan L Roth; Steven F Maier; Linda R Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

7.  Analgesia or addiction?: implications for morphine use after spinal cord injury.

Authors:  Sarah A Woller; Georgina L Moreno; Nigel Hart; Paul J Wellman; James W Grau; Michelle A Hook
Journal:  J Neurotrauma       Date:  2012-04-02       Impact factor: 5.269

8.  Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy.

Authors:  Lisa C Loram; Peter M Grace; Keith A Strand; Frederick R Taylor; Amanda Ellis; Debra Berkelhammer; Melissa Bowlin; Bryce Skarda; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2012-08-10       Impact factor: 7.217

9.  Long-term Follow-up of Cutaneous Hypersensitivity in Rats with a Spinal Cord Contusion.

Authors:  Ji-In Jung; Junesun Kim; Seung Kil Hong; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2008-12-31       Impact factor: 2.016

10.  Intrathecal morphine attenuates recovery of function after a spinal cord injury.

Authors:  Michelle A Hook; Georgina Moreno; Sarah Woller; Denise Puga; Kevin Hoy; Robyn Balden; James W Grau
Journal:  J Neurotrauma       Date:  2009-05       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.